Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

類似資料

• Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib
  著者:: Mizoguchi, Izuru, 等
  出版事項: (2013)
• Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
  著者:: Ohyashiki, Junko H, 等
  出版事項: (2014)
• Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib
  著者:: Ohyashiki, Kazuma, 等
  出版事項: (2016)
• Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
  著者:: Seiichiro Katagiri, 等
  出版事項: (2017-01-01)
• Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
  著者:: Katagiri, Seiichiro, 等
  出版事項: (2017)